On Mar 30, we issued an updated research report on Nordson Corporation (NDSN - Free Report) .
In the past three months, this Zacks Rank #3 (Hold) stock has returned 1% compared with the industry’s growth of 86.5%.
Present Scenario
Nordson is well poised to benefit from strength in its test & inspection, consumer non-durable, industrial and fluid dispense end markets in the quarters ahead. Also, going forward, implementation of Nordson Business System is likely to prove beneficial. For fiscal 2021 (ended October 2021), it anticipates revenue growth of 4-6% on a year-over-year basis.
Also, Nordson believes in strengthening and expanding its businesses through acquisitions. In this regard, its acquisition of vivaMOS Ltd. (September 2020) has been strengthening its test and inspection capabilities. Also, the Fluortek buyout (June 2020) has been its boosting medical product lines. Notably, for the company’s Advanced Technology Solutions segment, acquired assets had a positive impact of 2% in the first quarter of fiscal 2021 (ended Jan 31, 2021).
Moreover, it rewards shareholders handsomely through dividend payments and share buybacks. For instance, in first-quarter fiscal 2021, the company used $22.7 million for paying out dividends and repurchasing shares worth $5.3 million.
However, though Nordson’s long-term debt decreased 8.1% sequentially to $981 million in the fiscal first-quarter, its cash and cash equivalent balance of $225.7 million does not seem impressive, considering its high debt profile.
Further, the company’s international businesses have exposed it to risks arising from unfavorable movements in foreign currencies and geopolitical issues. It’s worth noting that in the fiscal first quarter, the company’s revenues declined 1.6% year over year in Japan.
Stocks to Consider
Some better-ranked stocks from the same space are Applied Industrial Technologies, Inc. (AIT - Free Report) , The Middleby Corporation (MIDD - Free Report) and Kadant Inc (KAI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Industrial delivered a positive earnings surprise of 21.92%, on average, in the trailing four quarters.
Middleby delivered a positive earnings surprise of 22.98%, on average, in the trailing four quarters.
Kadant delivered a positive earnings surprise of 30.95%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On Mar 30, we issued an updated research report on Nordson Corporation (NDSN - Free Report) .
In the past three months, this Zacks Rank #3 (Hold) stock has returned 1% compared with the industry’s growth of 86.5%.
Present Scenario
Nordson is well poised to benefit from strength in its test & inspection, consumer non-durable, industrial and fluid dispense end markets in the quarters ahead. Also, going forward, implementation of Nordson Business System is likely to prove beneficial. For fiscal 2021 (ended October 2021), it anticipates revenue growth of 4-6% on a year-over-year basis.
Also, Nordson believes in strengthening and expanding its businesses through acquisitions. In this regard, its acquisition of vivaMOS Ltd. (September 2020) has been strengthening its test and inspection capabilities. Also, the Fluortek buyout (June 2020) has been its boosting medical product lines. Notably, for the company’s Advanced Technology Solutions segment, acquired assets had a positive impact of 2% in the first quarter of fiscal 2021 (ended Jan 31, 2021).
Moreover, it rewards shareholders handsomely through dividend payments and share buybacks. For instance, in first-quarter fiscal 2021, the company used $22.7 million for paying out dividends and repurchasing shares worth $5.3 million.
However, though Nordson’s long-term debt decreased 8.1% sequentially to $981 million in the fiscal first-quarter, its cash and cash equivalent balance of $225.7 million does not seem impressive, considering its high debt profile.
Further, the company’s international businesses have exposed it to risks arising from unfavorable movements in foreign currencies and geopolitical issues. It’s worth noting that in the fiscal first quarter, the company’s revenues declined 1.6% year over year in Japan.
Stocks to Consider
Some better-ranked stocks from the same space are Applied Industrial Technologies, Inc. (AIT - Free Report) , The Middleby Corporation (MIDD - Free Report) and Kadant Inc (KAI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Industrial delivered a positive earnings surprise of 21.92%, on average, in the trailing four quarters.
Middleby delivered a positive earnings surprise of 22.98%, on average, in the trailing four quarters.
Kadant delivered a positive earnings surprise of 30.95%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AIT - FREE
Get the latest research report on NDSN - FREE
Get the latest research report on MIDD - FREE
Get the latest research report on KAI - FREE